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E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3 35were used. EFS was analysed for 100 patients treated with high-
dose-chemotherapy.
Results: Gene-expression and iFISH allow a molecular classifica-
tion of MM (expression-cytogenetic (EC) classification): (1.1)
CCND1-expression and 11q13+, (1.2) CCND1-expression, translo-
cations involving 11q13, (2.1) CCND2-overexpression without
11q13+, t(11;14), t(4;14), (2.2) CCND2-overexpression, t(4;14),
FGFR3-upregulation.
Conclusion: EC-groups defined by the predictor show a distinc-
tive pattern in gene expression and significantly different EFS.
EC-groups and B2M represent independent prognostic
parameters.1,2
doi:10.1016/j.ejcsup.2006.04.081
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Switzerland; 2Signature Diagnostics AG, Potsdam, Germany.Background: Classification of patient samples is an important
aspect of cancer diagnosis and treatment. Recent microarray
studies have shown that cancer classification by gene expression
profiling is feasible and provides clinicians with additional infor-
mation to choose the most appropriate forms of treatment.
Patients and Methods: A ‘‘genetic algorithm’’, using K-Nearest
Neighbour-Classification was used to identify diagnostically rele-
vant probe set combinations (classifier) to classify patients with
sporadic colorectal cancer into stages without nodal and distant
metastasis (UICC I/II) and patients with advanced CRC with nodal
and distant metastasis (UICC III/IV). The algorithm was feeded
with the 5% top and 5% bottom probe sets after statistical ranking
(Golub, Wilcoxon, foldchange).
Results: Thus 2228 probe sets have been used as a starting pool.
Discriminating probe set combinations have been identified in a
training data set and checked using a non-overlapping test set.
Probe sets classifying correctly in more than 99% could be identi-
fied for tumor vs. normal tissue distinction and for UICC I/II vs.
III/IV distinction in the training set. In non-overlapping test-set
tumor/normal classifier performed well (90%), whereas UICC clas-
sifier only reached 60% performance.
Conclusion: Most likely generalization properties of the signa-
tures are poor because data representativeness is not sufficient
using this approach. Sample number is quite appropriate to iden-
tify differentially expressed genes between tumor and normal tis-
sues but it is likely to be insufficient to reliably reveal
differentially expressed genes between diverse prognostic stages
based on UICC classification in colorectal cancer.
doi:10.1016/j.ejcsup.2006.04.082P23. A NEW FAMILY OF KIAA1245 GENES WITH AND
WITHOUT THE HERV-K LTRS IN THEIR INTRONS
Anna E. Illarionova, Tatyana V. Vinogradova, Pavel A. Zhulidov,
Eugeny D. Sverdlov. Shemyakin-Ovchinnikov Institute of Bioorganic
Chemistry, Russian Academy of Sciences, Moscow, Russia.
A transcript containing the long terminal repeat (LTR) and the
sequence homologous to the KIAA1245 mRNA fragment were
revealed among the transcribed LTRs of human endogenous
viruses of the K family in normal and tumor tissues. Ten other
sequences with a high level of homology to the KIAA1245 mRNA
were found in the GenBank. The intron-exon structures were
determined for all the sequences, and their exon sequences were
compared. The comparison showed that they differ both in the
extent of the exon homology and in the presence or absence of
the HERV-K LTR in the second intron. The revealed sequences
form a new gene family that comprises at least four subfamilies.
Two of these subfamilies have the LTR, and the other two do not.
We showed by PCR that the LTR was integrated into the introns
after the divergence of the orangutan evolutionary branch from
other hominoids but before the divergence of the gorilla branch,
i.e., 8–13 million years ago. The total expression of the genes of
this family was examined in a number of tissues. It was shown
that LTR-containing genes of this family expressed in tumor,
embryonic tissues and in transformed human cell cultures, in
explored normal tissues of the mature organism the expression
of genes of this family was not detected.
doi:10.1016/j.ejcsup.2006.04.083
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Background: Monoclonal antibody Ki-67 is a well-established
and widely used marker to access cell proliferation activity, par-
ticularly in tumors. Ki-67 is directed against a nuclear antigen
(pKi-67) which is solely expressed in actively proliferating cells
during all phases of the cell cycle, but it is absent in quiescent
cells. To investigate polymorphisms or mutations of the pKi-67
promoter we sequenced the promoter region of the pKi-67 gene
of 50 colorectal cancer patients and 24 healthy donors. To find dif-
ferences in the biologic relevance of polymorphisms we mea-
sured the promoter-activity of all detected variants.
Methods: The pKi-67 promoter region was amplified using Pfu-
polymerase, randomly cloned into the pCR-Blunt II-Topo-vector,
and cycle-sequenced using Thermosequenase. Firefly-luciferase
reporter plasmids were constructed by subcloning of the
sequence-controlled inserts into the pGL3-Basic-vector. The
activity of the reporter plasmids was measured using the Dual-
Luciferase Reporter Assay.
Results: After comparison of the cloned promoter sequences we
found four polymorphisms (three SNPs and one tetranucleotide
repeat) at position -518(A > G), -351(T > C), 186((GGGC)3 > (GGGC)5),
36 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3and -49(G > T) from the transcription start site. We could demon-
strate that the variants -186(GGGC)5 (p < 0.05), and -49T (p = 0.05)
were significantly or strongly associated with colorectal cancer
as compared to the healthy controls. We found the highest pro-
moter activity to be associated with -186(GGGC)3 and -49T.
Conclusion: These results suggest that the two pKi-67 promoter
polymorphisms 186(GGGC)3 > (GGGC)5 and -49G > T located in the
basic promoter may play a crucial rule in the development of
colorectal cancer.
doi:10.1016/j.ejcsup.2006.04.084
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D. Stanciute, J. Didziapetriene, F. Jankevicius. Institute of Oncology,
Vilnius University, Lithuania.
Introduction: Ample evidence indicates that MMPs contribute in
multiple ways to all stages of malignant progression, including
tumor invasion, blood vessel penetration, metastases and tumor
angiogenesis. MMP-9 has been found to be specifically associated
with prostate cancer metastasis. A number of DNA polymor-
phisms in the MMP genes are associated with differences in
MMP activity. However, the relationship between the polymor-
phism and susceptibility of cancer remains ambiguous. A cyto-
sine (C) – thymidine (T) single nucleotide polymorphism (SNP)
at position -1562 in the MMP-9 promoter is reported to affect
expression of this gene.
Aim: To determine the prevalence of a single nucleotide poly-
morphism (-1562 C/T) in the MMP-9 gene promoter in cancer
patients and evaluate it’s correlation with tumor type and stage.
Methods and Materials: DNA from the cancer patients’ blood
was extracted and amplified with PCR. PCR-RFLP method was
used to determine MMP-9 polymorphism in 18 prostate cancer
cases, 4 benign prostate hyperplasia cases, 14 invasive bladder
cancer cases, 5 non-invasive bladder cancer cases, 4 renal cancer
cases and 1 adrenal gland cancer case.
Results: Prevalence of C/C, C/T, T/T genotypes was similar
among bladder and renal cancer patients. In prostate cancer
patients a significant association (P = 0.0052) between clinical
stage and MMP-9 polymorphism was found.
Conclusion: Our data demonstrate that MMP-9 (-1562 C/T) poly-
morphism may modify susceptibility to prostate cancer. We
hypothesized that this polymorphism might act as a genetic
modifier in the development and progression of prostate cancer.
Additional studies with larger population are warranted.
doi:10.1016/j.ejcsup.2006.04.085
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Background: Despite compelling data demonstrating a direct
link between altered expression of S100 proteins located on
human chromosome 1q21 and epithelial malignancies, the
knowledge of their function and mode of action in epithelial cells
and in tumor promotion or progression is largely unknown.
Methods: Gene expression profiling of the in vivo model of
chemically induced skin carcinogenesis revealed differential reg-
ulation of genes coding for S100 proteins. Subsequent studies
using in vitro models and tissue microarrays are currently
extended by to suitable in vivo models.
Results: Here, we have identified a novel signaling pathway in
epithelial cells initiated by extracellular S100A8/A9 resulting in
the activation of AP-1-dependent gene expression. Importantly,
co-expression of S100A3 inhibits S100A8/A9 mediated AP-1 acti-
vation, which is in line with repression of this gene during skin
carcinogenesis suggesting a negative role for S100A3 in epithelial
malignancy. We found elevated levels of MMP2 and MMP9, two
well-known AP-1 regulated genes, and identified S100A6 as an
additional target gene of S100A8/A9 signaling. Moreover, signifi-
cant co-expression of S100A8 and S100A9 together with phos-
phorylation of c-Jun and elevated S100A6 protein levels were
evident in eSCC. The in vivo relevance of S100A8/A9 interaction
with RAGE is discussed.
Conclusion: Our data suggest that targeting the net activity of
S100 induced signaling represents an auspicious strategy for can-
cer prevention and/or therapy.
doi:10.1016/j.ejcsup.2006.04.086
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Background: One of the most common properties of cancer is
genomic instability, a leading cause of which are defects of the
DNA damage response (DDR). DDR defects in tumors and germ-
line have been linked to clinical outcome and cancer susceptibil-
ity, respectively. Among DDR regulators, the nuclear checkpoint
kinase Chk1 is an established transducer of ATR- and ATM-
dependent signalling in response to DNA damage. Additional
functions of Chk1 include regulation of unperturbed cell cycle
progression. Recently, we have shown that Chk1 localizes to inter-
